ClinicalTrials.gg
CompletedNCT01679613Updated Nov 27, 2014Results posted

Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers

A Phase 1 interventional study of Nintedanib and Nintedanib in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The objective of the current study is to investigate the relative bioavailability of a single dose of nintedanib low or high dose with and without coadministration of ketoconazole at steady state

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. healthy male subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    1 Nintedanib (Reference)

    single dose, oral with 240 ml water

    Drug: Nintedanib

  • Experimental
    2 Nintedanib + Ketoconazole (Test)

    Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water

    Drug: Ketoconazole · Drug: Nintedanib

  • Experimental
    3 Nintedanib (Reference)

    single dose, oral with 240 ml water

    Drug: Nintedanib

  • Experimental
    4 Nintedanib + Ketoconazole (Test)

    Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water

    Drug: Nintedanib · Drug: Ketoconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)

    AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

    Time frame: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration

  2. Maximum Measured Concentration (Cmax)

    Cmax represents the maximum concentration of nintedanib in plasma For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

    Time frame: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration

Secondary outcomes

  1. Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)

    AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from time 0 to the last quantifiable nintedanib plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

    Time frame: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration

07

Results

Posted Nov 27, 2014

Participant flow

Participant flow — Overall Study
MilestoneNintedanib (Pilot Part)/ Nintedanib+Ketoconazole (Pilot Part)Nintedanib+Ketoconazole (Pilot Part)/ Nintedanib (Pilot Part)Nintedanib (Main Part)/ Nintedanib+Ketoconazole (Main Part)Nintedanib+Ketoconazole (Main Part)/ Nintedanib (Main Part)
Started441313
Received nintedanib (pilot)4300
Received nintedanib+ketoconazole (pilot)4400
Received nintedanib (main)001311
Received nintedanib+ketoconazole (main)001313
Completed431111
Not completed0122
Withdrew: Other than stated above0122

Outcome measures

PrimaryArea Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

Time frame:
1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)
ng*h/mLNintedanibNintedanib + Ketoconazole
Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)38.6 ± 42.561.3 ± 40.4
Statistical analysis
  • Nintedanib vs Nintedanib + Ketoconazole · ANOVA · p = 1.0000 (p-value for ratio outside interval 0.8 - 1.25) · Geometric mean ratio in percentage: 160.48 · 90% CI 148.245 to 173.736Ratio calculated as nintedanib+ketoconazole divided by nintedanib (in %). The standard deviation is actually the geometric coefficient of variation (gCV).
PrimaryMaximum Measured Concentration (Cmax)

Cmax represents the maximum concentration of nintedanib in plasma For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

Time frame:
1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration
Reported as:
Geometric mean · ng/mL
Maximum Measured Concentration (Cmax)
ng/mLNintedanibNintedanib + Ketoconazole
Maximum Measured Concentration (Cmax)4.19 ± 71.07.13 ± 44.4
Statistical analysis
  • Nintedanib vs Nintedanib + Ketoconazole · ANOVA · p = 1.0000 (p-value for ratio outside interval 0.8 - 1.25) · Geometric mean ratio in percentage: 179.62 · 90% CI 157.557 to 204.779The standard deviation is actually the gCV (in %). Ratio calculated as nintedanib+ketoconazole divided by nintedanib
SecondaryArea Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)

AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from time 0 to the last quantifiable nintedanib plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

Time frame:
1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration
Reported as:
Geometric mean · ng*h/mL
Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)
ng*h/mLNintedanibNintedanib + Ketoconazole
Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)35.7 ± 47.859.4 ± 40.8
Statistical analysis
  • Nintedanib vs Nintedanib + Ketoconazole · ANOVA · p = 1.000 (p-value for ratio outside interval 0.8 to 1.25) · Geometric mean ratio in percentage: 168.09 · 90% CI 155.252 to 181.981The standard deviation is actually the gCV. Ratio calculated as nintedanib+ketoconazole divided by nintedanib (in %).

Adverse events

Collected over From the first trial drug administration until 18 days after the last trial drug administration, up to 32 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketoconazole—0/34 (0%)2/34 (5.9%)
Nintedanib—0/31 (0%)6/31 (19.4%)
Nintedanib + Ketoconazole—0/29 (0%)6/29 (20.7%)
Most frequent other events
Most frequent other events
EventKetoconazoleNintedanibNintedanib + Ketoconazole
HeadacheNervous system disorders2/345/315/29
Back painMusculoskeletal and connective tissue disorders0/340/312/29
NasopharyngitisInfections and infestations0/342/311/29

Baseline characteristics

The treated set (TS) includes all subjects who were dispensed study medication and were documented to have taken at least one dose of study medication (nintedanib or ketoconazole).

Age, Continuous
Age, Continuous(years)Overall Study
Mean35.9 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female0
Male34
08

Study locations

1 site
  • 1199.161.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

References and documents

Publications

  • Luedtke D, Marzin K, Jungnik A, von Wangenheim U, Dallinger C. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541. doi: 10.1007/s13318-018-0467-9. PubMed 29500603 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2012
First posted
Sep 6, 2012
Start
Sep 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Nov 27, 2014
Last update
Nov 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01679613
Responsible party
Sponsor
First posted
Sep 6, 2012
Start date
Sep 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Nov 27, 2014
Last update
Nov 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion